Cargando…

CD45RA(+)CCR7(−) CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab

BACKGROUND: Checkpoint inhibitors have become standard care of treatment for non-small cell lung cancer (NSCLC), yet only a limited fraction of patients experiences durable clinical benefit, highlighting the need for markers to stratify patient populations. METHODS: To prospectively identify patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kunert, Andre, Basak, Edwin A., Hurkmans, Daan P., Balcioglu, Hayri E., Klaver, Yarne, van Brakel, Mandy, Oostvogels, Astrid A. M., Lamers, Cor H. J., Bins, Sander, Koolen, Stijn L. W., van der Veldt, Astrid A. M., Sleijfer, Stefan, Mathijssen, Ron H. J., Aerts, Joachim G. J. V., Debets, Reno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555948/ https://www.ncbi.nlm.nih.gov/pubmed/31176366 http://dx.doi.org/10.1186/s40425-019-0608-y

Ejemplares similares

Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes
por: Klaver, Yarne, et al.
Publicado: (2020)

T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients
por: Klaver, Yarne, et al.
Publicado: (2016)

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu
por: Kunert, Andre, et al.
Publicado: (2013)

Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS
por: de Goeje, Pauline L., et al.
Publicado: (2018)

Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer
por: Hurkmans, Daan P., et al.
Publicado: (2020)

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients
por: Bins, Sander, et al.
Publicado: (2018)

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy
por: de With, Mirjam, et al.
Publicado: (2021)

A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
por: Hurkmans, Daan P., et al.
Publicado: (2019)

Rintatolimod (Ampligen(®)) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program
por: el Haddaoui, Hassana, et al.
Publicado: (2022)

A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
por: Rijnders, Maud, et al.
Publicado: (2022)

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
por: Hurkmans, Daan P., et al.
Publicado: (2021)

Frequency of Peripheral CD8+ T Cells Expressing Chemo-Attractant Receptors CCR1, 4 and 5 Increases in NPC Patients with EBV Clearance upon Radiotherapy
por: Mahajan, Shweta, et al.
Publicado: (2023)

Intratumoral Niches of B Cells and Follicular Helper T Cells, and the Absence of Regulatory T Cells, Associate with Longer Survival in Early-Stage Oral Tongue Cancer Patients
por: Phanthunane, Chumut, et al.
Publicado: (2022)

Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report
por: de Joode, Karlijn, et al.
Publicado: (2023)

Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis
por: ten Berge, Deirdre M.H.J., et al.
Publicado: (2019)

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer
por: Hurkmans, Daan P, et al.
Publicado: (2020)

Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma
por: Hurkmans, Daan P, et al.
Publicado: (2020)

TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune Targets
por: Straetemans, Trudy, et al.
Publicado: (2012)

Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure
por: Bins, Sander, et al.
Publicado: (2016)

Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint Inhibition
por: de Joode, K., et al.
Publicado: (2021)

Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient
por: Siddiqui, Imran, et al.
Publicado: (2016)

Preclinical imaging of the co-stimulatory molecules CD80 and CD86 with indium-111-labeled belatacept in atherosclerosis
por: Meletta, Romana, et al.
Publicado: (2016)

Fine Tuning and Efficient T Cell Activation with Stimulatory aCD3 Nanoarrays
por: Matic, Jovana, et al.
Publicado: (2013)

Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?
por: Ville, Simon, et al.
Publicado: (2015)

CD46 is a potent co-stimulatory receptor for expansion of human IFN-γ-producing CD8(+) T cells
por: Hansen, Aida S., et al.
Publicado: (2018)

Engagement of distinct epitopes on CD43 induces different co‐stimulatory pathways in human T cells
por: Modak, Madhura, et al.
Publicado: (2016)

Analyzing Flow Cytometry or Targeted Gene Expression Data Influences Clinical Discoveries—Profiling Blood Samples of Pancreatic Ductal Adenocarcinoma Patients
por: de Koning, Willem, et al.
Publicado: (2023)

V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma
por: Mutsaers, Pim, et al.
Publicado: (2021)

Stimulatory role of interleukin 10 in CD8(+) T cells through STATs in gastric cancer
por: Xi, Jianjun, et al.
Publicado: (2017)

Tumor mutational load, CD8(+) T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients
por: Hurkmans, Daan P., et al.
Publicado: (2020)

Lack of B and T cell reactivity towards IDH1(R132H) in blood and tumor tissue from LGG patients
por: Weenink, Bas, et al.
Publicado: (2019)

CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T cells
por: Guercio, Marika, et al.
Publicado: (2020)

CD4+ T-cell alloreactivity after haploidentical hematopoietic stem cell transplantation
por: Kalin, Burak, et al.
Publicado: (2020)

T cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic pulmonary fibrosis survival
por: Bonham, Catherine A., et al.
Publicado: (2019)

CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development
por: Hashimoto, Kenji
Publicado: (2021)

Non-Stimulatory pMHC Enhance CD8 T Cell Effector Functions by Recruiting Coreceptor-Bound Lck
por: Zhao, Xiang, et al.
Publicado: (2021)

Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens
por: Weenink, Bas, et al.
Publicado: (2019)

An Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8α Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT
por: Schaft, Niels, et al.
Publicado: (2013)

Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation
por: Rambaldi, Benedetta, et al.
Publicado: (2022)

Glycosylation Provides Both Stimulatory and Inhibitory Effects on Cell Surface and Soluble CD44 Binding to Hyaluronan
por: Skelton, Timothy P., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_nd5jp3p96284ucte5frmqftr1v